Quantum BioPharma (NASDAQ: QNTM) has filed a supplement to its September 28, 2026, management information circular ahead of its annual general and special meeting of shareholders scheduled for November 10, 2026. The supplement corrects and restates the proposed special resolution authorizing a consolidation of the company’s Class A multiple voting shares and Class B subordinate voting shares, providing critical clarity on how fractional shares will be treated and how voting power will be capped.
Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up. This standard rounding convention ensures a predictable and equitable outcome for shareholders, avoiding the creation of fractional shares that cannot be issued. The company also clarified that it will implement measures to cap the aggregate voting power of multiple voting shareholders at 70% if cancellations of Class B subordinate voting shares would otherwise cause that threshold to be exceeded. This cap is designed to prevent any unintended concentration of control that could arise from the consolidation process, thereby protecting the interests of subordinate voting shareholders and maintaining a balanced governance structure.
The filing matters because share consolidations can materially affect the number of shares outstanding, earnings per share calculations, and the relative voting influence of different share classes. By proactively addressing the treatment of fractional shares and the potential for voting power to exceed 70%, Quantum BioPharma is mitigating ambiguity and reducing the risk of shareholder confusion or disputes ahead of the vote. Previously submitted proxies will remain valid unless revoked or changed, and shareholders are encouraged to review the supplemental materials before the meeting. The full press release is available at https://ibn.fm/aqzMe.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
For investors, the supplement underscores Quantum BioPharma’s commitment to transparent corporate governance and orderly capital structure management. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The filing was distributed through MissionIR, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets.
